1 EMPLOYMENT AGREEMENT

Employment Agreement Amendment

Section 1.1 is amended to change your position title to “Senior Vice President, Intellectual Property and Technology Development, and Chief Patent Officer”.

Section 2.1(a) is amended to increase your annual Base Salary to $300,000.

Section 2.1(f) is amended to increase your target cash incentive compensation payment to 40% of your Base Salary, provided that your target payment for 2015 will be prorated based on your current target and your current annual Base Salary for the period from January 1, 2015 to the effective date of this letter and your amended target and amended Base Salary from the effective date of this letter to December 31, 2015.

/s/ Geoffrey Cox

November 5, 2015

Dr. Geoffrey Cox

Interim CEO

/s/ Lana Janes

November 5, 2015

Dr. Lana Janes

Dr. Janes has been employed by QLT since August 15, 2005 and, effective January 1, 2010 was appointed to the position of Vice President, Intellectual Property and Chief Patent Officer.

In consideration of the salary increase that Dr. Janes received effective January 1, 2010, QLT and Dr. Janes agree to replace and supercede the employment agreement dated July 29, 2005 with this agreement which sets out the new terms and conditions of Dr. Janes’ employment with QLT in the position of Vice President, Intellectual Property and Chief Patent Officer.

POSITION AND DUTIES

Position – Effective January 1, 2010, Dr. Janes is employed by QLT in the position of Vice President, Intellectual Property and Chief Patent Officer and Dr. Janes agrees to be employed by QLT in that position, subject to the terms and conditions of this Agreement.

Duties, Reporting and Efforts – In the performance of her duties as Vice President, Intellectual Property and Chief Patent Officer, Dr. Janes will:

Overall Responsibilities – Dr. Janes will have overall responsibility for Intellectual Property within QLT.

Report – Report, as and when required, to the President and Chief Executive Officer of QLT or such person appointed by the Board of Directors of QLT (the “Board”) to act in that capacity.

Best Efforts and Compliance with Policies, etc. – Use her best efforts, industry and knowledge to carry out the duties and functions of the Vice President, Intellectual Property and Chief Patent Officer, to comply with all of QLT’s rules, regulations, policies (including QLT’s Code of Ethics and Code of Exemplary Conduct) and procedures, as established from time to time and to ensure that QLT is at all times in compliance with applicable provincial, state, federal and other

governing statutes, policies and regulations. Dr. Janes confirms that she is not now nor has in the past been debarred by the United States Food and Drug Administration under the Food, Drug and Cosmetic Act or under the Generic Drug Enforcement Act and she has never been convicted under the Food, Drug and Cosmetic Act or under the Generic Drug Enforcement Act, or under any other federal law for conduct relating to the development or approval of a drug product and/or relating to a drug product. In the event that Dr. Janes is, or learns that she will be (i) debarred under the Food, Drug and Cosmetic Act or under the Generic Drug Enforcement Act, or (ii) convicted under the Food, Drug and Cosmetic Act or under the Generic Drug Enforcement Act or under any other federal law for conduct relating to the development or approval of a drug product and/or relating to a drug product, she will immediately notify QLT in writing.

Working Day – Devote the whole of her working day attention and energies to the business and affairs of QLT.

COMPENSATION

Annual Compensation – In return for her services under this Agreement, QLT agrees to pay or otherwise provide the following total annual compensation (in Canadian dollars) to Dr. Janes:

Base Salary – A base salary in the amount of CAD $208,202 in 24 equal installments payable semi-monthly in arrears, subject to periodic annual reviews at the discretion of QLT.

Benefit Plans – Coverage for Dr. Janes and her eligible dependents under any employee benefit plans provided by/through QLT to its employees, subject to:

Each plan’s terms for eligibility,

Dr. Janes taking the necessary steps to ensure effective enrollment or registration under each plan, and

Customary deductions of employee contributions for the premiums of each plan.

Expense Reimbursement – Reimbursement, in accordance with QLT’s Policy and Procedures Manual (as amended from time to time), of all reasonable business expenses, including accommodation and/or travel expenses incurred by Dr. Janes, subject to her maintaining proper accounts and providing documentation for these expenses upon request. Collectively, these expenses and payments are the “Expenses”.

Vacation – Four weeks of paid vacation per year, as may be increased from time to time in accordance with QLT’s vacation policy for officer level employees. As per the Company’s Policy and Procedures Manual (as amended from time to time), unless agreed to in writing by the Company:

All vacation must be taken within the calendar year in which it is earned by Dr. Janes, and

Vacation entitlement will not be cumulative from calendar year to calendar year; except that Dr. Janes may carry forward 75 hours of vacation from the calendar year in which it is earned to the following calendar year (but not subsequent years).

RRSP Contributions – Provided the conditions set out below have been satisfied, in January or February of the year following the year in which the income is earned by Dr. Janes (the “Income Year”), QLT will make a contribution of up to 7% of Dr. Janes’ annual base salary for the Income Year to Dr. Janes’ Registered Retired Savings Plan (“RRSP”). The contribution to Dr. Janes’ RRSP as set out above is subject to the following conditions:

The maximum contribution to be made by QLT to Dr. Janes’ RRSP is 50% of the annual limit for Registered Retirement Savings Plans as established by Canada Revenue Agency for the Income Year,

Dr. Janes must have contributed an equal amount into her RRSP, and

Dr. Janes is still actively employed by QLT when the matching contribution would otherwise be made.

Cash Incentive Compensation Plan – Participation in the Cash Incentive Compensation Plan offered by QLT to its officers in accordance with the terms of such Plan, as amended from time to time by the Board. The amount of that payment each year will be determined at the sole discretion of the Chief Executive Officer and the Board and is to be based on the performance of Dr. Janes and QLT relative to pre-set individual and corporate objectives and milestones for the immediately preceding fiscal year. In order to receive payment, Dr. Janes must be employed by QLT at the time when the Cash Incentive Compensation Plan is otherwise actually paid to eligible employees (which usually occurs in February or March of the year following the calendar year in which such Cash Incentive Compensation amount relates) The Board of Directors has the discretion to alter the cash incentive compensation plan and payments thereunder.

Stock Option Plan – Participation in any stock option plan offered by QLT to its officers, in accordance with the terms of the plan in effect at the time of the stock option offer(s).

RESIGNATION

Resignation – Dr. Janes may resign from her employment with QLT by giving QLT 60 days prior written notice (the “Resignation Notice”) of the effective date of her resignation. On receiving a Resignation Notice, QLT may elect to provide the following payments in lieu of notice to Dr. Janes and require her to leave the premises forthwith:

Base Salary – Base salary owing to Dr. Janes for the 60-day notice period.

Benefits – Except as set out below in this subparagraph 3.1(b), for the 60-day notice period, all employee benefit plan coverage enjoyed by Dr. Janes and her eligible dependents prior to the date of her Resignation Notice. Dr. Janes acknowledges and agrees that any short and long term disability plans provided through QLT will not be continued beyond the last day that Dr. Janes works at QLT’s premises (the “Last Active Day”).

Expense Reimbursement – Reimbursement (in accordance with QLT’s Policy and Procedures Manual, as amended from time to time) of all reasonable business related expenses, including accommodation and/or travel expenses incurred by Dr. Janes prior to her Last Active Day, subject to the expense reimbursement provisions set out in subparagraph 2.1(c).

Vacation Pay – Payment in respect of accrued but unpaid vacation pay owing to Dr. Janes as at the expiry of the 60-day notice period.

Prorated RRSP Contribution – Payment of any unpaid RRSP contribution in respect of any calendar year preceding the calendar year in which the 60-day period expires and a prorated contribution to Dr. Janes’ RRSP, the pro-ration to be with respect to the portion of the current

calendar year worked by Dr. Janes, up to and including the 60-day notice period, and the contribution to be subject to the conditions set out in subparagraph 2.1(e), except condition III.

Others – In the event of resignation of Dr. Janes as set out in paragraph 3.1, the parties agree:

No Bonus – Dr. Janes will have no entitlement to participate in QLT’s Cash Incentive Compensation Plan for the year in which she resigns her employment with QLT; and

Stock Option Plan – Dr. Janes’ participation in any stock option plan offered by QLT to its employees will be in accordance with the terms of the plan in effect at the time of the stock option grant(s) to Dr. Janes and the applicable stock option agreement applicable to such stock options.

RETIREMENT

Retirement – Effective the date of retirement (as defined in QLT’s Policy and Procedures Manual, as amended from time to time) of Dr. Janes from active employment with QLT, the parties agree that:

This Agreement – Subject to the provisions of paragraph 10.6, both parties’ rights and obligations under this Agreement will terminate without further notice or action by either party.

Stock Options – Dr. Janes’ participation in any stock option plan offered by QLT to its employees will be in accordance with the terms of the plan in effect at the time of the stock option grant(s) to Dr. Janes and the applicable stock option agreement applicable to such stock options.

TERMINATION

Termination for Cause – QLT reserves the right to terminate Dr. Janes’ employment at any time for any reason. Should Dr. Janes be terminated for cause, she will not be entitled to any advance notice of termination or pay in lieu thereof.

Termination Other than for Cause – QLT reserves the right to terminate Dr. Janes’ employment at any time without reason or cause. However, if QLT terminates Dr. Janes’ employment for any reason other than for cause, then, except in the case of Dr. Janes becoming completely disabled (which is provided for in paragraph 5.6) and subject to the provisions set forth below, Dr. Janes will be entitled to receive notice, pay and/or benefits (or any combination of notice, pay and/or benefits) as more particularly set out in paragraph 5.3.

Severance Notice and Pay – In the event QLT terminates Dr. Janes’ employment as set out in paragraph 5.2, Dr. Janes will be entitled to:

Notice – Advance written notice of termination (“Severance Notice”), or pay in lieu thereof (“Severance Pay”), or any combination of Severance Notice and Severance Pay, as more particularly set out below:

A minimum of nine (9) months Severance Notice, or Severance Pay in lieu thereof, and

One additional month’s Severance Notice, or Severance Pay in lieu thereof, for each complete year of continuous employment with QLT (which, for greater certainty commenced on August 15, 2005),

Benefits – Except as set out below, for 30 days after Dr. Janes’ Last Active Day, all employee benefit plan coverage enjoyed by Dr. Janes and her dependents prior to the date of termination. Thereafter, and in lieu of employee benefit plan coverage, Dr. Janes will receive

compensation (“Benefits Compensation”) in the amount of 10% of her base salary for the balance of her Severance Notice period. Dr. Janes acknowledges and agrees that short and long term disability plans provided through QLT will not be continued beyond Dr. Janes’ Last Active Day.

Out Placement Counseling – QLT will pay to an out placement counseling service (to be agreed to by Dr. Janes and QLT, each acting reasonably) a maximum of CAD $5,000 for assistance rendered to Dr. Janes in seeking alternative employment.

Other Compensation – QLT will provide the following additional compensation:

QLT will reimburse (in accordance with QLT’s Policy and Procedures Manual, as amended from time to time) Dr. Janes for all Expenses properly and reasonably incurred by Dr. Janes on or prior to her Last Active Day, subject to the expense reimbursement provisions set out in subparagraph 2.1(c).

QLT will make a payment to Dr. Janes in respect of her accrued but unpaid vacation pay to the date of termination of her employment with QLT.

QLT will make a prorated contribution to Dr. Janes’ RRSP, the pro-ration to be with respect to the portion of the current calendar year worked by Dr. Janes and the contribution to be subject to the conditions set out in subparagraph 2.1(e), except condition III.

QLT will make a prorated payment to Dr. Janes in respect of her entitlement to participate in QLT’s Cash Incentive Compensation Plan, the pro-ration to be with respect to the portion of the current calendar year worked by Dr. Janes and the entitlement to be at the target level Dr. Janes would have otherwise been eligible to receive in the current calendar year if all corporate, and, if applicable, individual goals were met but not exceeded, provided that if the Last Active Day precedes the date that the amount under the Cash Incentive Compensation Plan or other incentive compensation is otherwise actually paid to QLT’s officers for a preceding year then Dr. Janes will also receive a payment in respect of her entitlement to participate in QLT’s Cash Incentive Compensation Plan and any other incentive compensation plan in place for the preceding calendar year and the entitlement to be at the target level Dr. Janes would have otherwise been eligible to receive in the that calendar year if all corporate, and individual goals were met but not exceeded

Dr. Janes’ participation in any stock option plan offered by QLT to its employees will be in accordance with the terms of the plan in effect at the time of the stock option offer(s) to Dr. Janes.

Acknowledgement and Release – Dr. Janes acknowledges and agrees that in the event QLT terminates Dr. Janes’ employment as set out in paragraph 5.2, in providing:

The Severance Notice or Severance Pay, or any combination thereof;

The Benefits Compensation;

Out placement counseling service as more particularly set out in subparagraph 5.3(c); and

The other compensation set out in subparagraph 5.3(d);

Duty to Mitigate

Duty to Mitigate – Dr. Janes acknowledges and agrees that if her employment is terminated without cause as set out in paragraph 5.2, her entitlement to Severance Pay, Benefits Compensation and other compensation as set out in paragraph 5.3 is subject to her duty to mitigate such payments by looking for and accepting suitable alternative employment or contract(s) for services. If Dr. Janes obtains new employment or contract(s) for services of four weeks or longer, Dr. Janes agrees that she will notify QLT of this fact in writing (the “New Employment Notice”) within five working days of such an occurrence and in this event the following provisions apply:

Dr. Janes acknowledges and agrees that her entitlement to Severance Pay and Benefits Compensation will cease as of the date on which her new employment or contract for services commences.

Within 10 working days of receipt of the New Employment Notice from Dr. Janes, QLT agrees that it will pay Dr. Janes a lump sum amount equivalent to 50% of the Severance Pay and Benefits Compensation as set out in paragraph 5.3 otherwise owing to Dr. Janes for the balance of the Severance Notice period.

Waiver of Duty to Mitigate on Delivery of Release – In the event that, either on or before the date of termination of Dr. Janes’ employment with QLT or within 30 days after termination of her employment, Dr. Janes executes and delivers to QLT a release in the form set out in Schedule A to this Agreement, the provisions of paragraph 5.5(a) shall be deemed to not apply and Dr. Janes shall have no duty to mitigate nor any reduction in the Severance Pay or Benefits Compensation in the event that she obtains alternative employment or contract(s) for service.

Termination Due to Inability to Act

Termination – QLT may immediately terminate this Agreement by giving written notice to Dr. Janes if she becomes completely disabled (defined below) to the extent that she cannot perform her duties under this Agreement either:

For a period exceeding six consecutive months, or

For a period of 180 days (not necessarily consecutive) occurring during any period of 365 consecutive days,

Payments – In the event of termination of Dr. Janes’ employment with QLT pursuant to the provisions of this paragraph 5.6, QLT agrees to pay to Dr. Janes Severance Pay and Benefits Compensation as set out in paragraph 5.3 and if Dr. Janes ceases to be completely disabled, then the provisions of paragraph 5.3(c) (out placement counseling) will apply.

Definition – The term “completely disabled” as used in this paragraph 5.6 will mean the inability of Dr. Janes to perform the essential functions of her position under this Agreement by reason of any incapacity, physical or mental, which the Board, based upon medical advice or an opinion provided by a licensed physician acceptable to the Board, determines to keep Dr. Janes from satisfactorily performing any and all essential functions of her position for QLT during the foreseeable future.

Death – Except as set out below, effective the date of death (the “Date of Death”) of Dr. Janes, this Agreement and both parties’ rights and obligations under this Agreement will terminate without further notice or action by either party. Within 30 days after the Date of Death (and the automatic concurrent termination of this Agreement), QLT will pay the following amounts to Dr. Janes’ estate:

Base Salary – Base salary owing to Dr. Janes up to her Date of Death.

Payment in Lieu of Benefits – In lieu of employee benefit coverage for her eligible dependents after her Date of Death, a payment in the amount of 10% of her annual base salary in effect at her Date of Death.

Expense Reimbursement – Reimbursement (in accordance with QLT’s Policy and Procedures Manual, as amended from time to time) of all reasonable Expenses incurred by Dr. Janes prior to her Date of Death, subject to the expense reimbursement provisions set out in subparagraph 2.1(c).

Vacation Pay – Payment in respect of accrued but unpaid vacation pay owing to Dr. Janes as at her Date of Death.

RRSP Contribution – A prorated contribution to Dr. Janes’ RRSP, the pro-ration to be with respect to the portion of the current calendar year worked by Dr. Janes and the contribution to be subject to the conditions set out in subparagraph 2.1(e), except condition III.

Bonus – A prorated payment to Dr. Janes in respect of her entitlement to participate in QLT’s Cash Incentive Compensation Plan, the pro-ration to be with respect to the portion of the current calendar year worked by Dr. Janes and the entitlement to be at the target level Dr. Janes would have otherwise been eligible to receive in the current calendar year if all corporate, and, if applicable, individual goals were met but not exceeded.

No Duplication – In the event that the Severance Pay provisions of this Agreement and the payment provisions of any other agreement that have been or may be entered into between QLT and Dr. Janes with respect to a change of control of QLT are both applicable, Dr. Janes agrees that she will give written notice to QLT with respect to which agreement she wishes to be paid out under and that she is not entitled to severance pay under both agreements.

CONFLICT OF INTEREST

Avoid Conflict of Interest – Except as set out below, during the term of her employment with QLT, Dr. Janes agrees to conduct herself at all times so as to avoid any real or apparent conflict of interest with the activities, policies, operations and interests of QLT. To avoid improper appearances, Dr. Janes agrees that she will not accept any financial compensation of any kind, nor any special discount or loan from persons, corporations or organizations having dealings or potential dealings with QLT, either as a customer or a supplier or a co-venturer. QLT and Dr. Janes acknowledge and agree that from time to time the President may consent in writing to activities by Dr. Janes which might otherwise appear to be a real or apparent conflict of interest.

No Financial Advantage – During the term of her employment with QLT, Dr. Janes agrees that neither she nor any members of her immediate family will take financial advantage of or benefit financially from information that is obtained in the course of her employment related duties and responsibilities unless the information is generally available to the public.

Comply with Policies – During the term of her employment with QLT, Dr. Janes agrees to comply with all written policies issued by QLT dealing with conflicts of interest.

Breach Equals Cause – Dr. Janes acknowledges and agrees that breach by her of the provisions of this Section 6 will be cause for immediate termination by QLT of her employment with QLT.

CONFIDENTIALITY

Information Held in Trust – Dr. Janes acknowledges and agrees that all business and trade secrets, confidential information and knowledge which Dr. Janes acquires during her employment with QLT relating to the business and affairs of QLT, its affiliates or subsidiaries or to technology, systems, programs, ideas, products or services which have been or are being developed or utilized by QLT, its affiliates or subsidiaries or in which QLT, its affiliates or subsidiaries are or may become interested (collectively, “Confidential Information”), will for all purposes and at all times, both during the term of Dr. Janes’ employment with QLT and at all times thereafter, be held by Dr. Janes in trust and used by Dr. Janes only for the exclusive benefit of QLT.

Non Disclosure – Dr. Janes acknowledges and agrees that both during the term of her employment with QLT and at all times thereafter, without the express or implied consent of QLT, Dr. Janes will not:

Disclose – Disclose to any company, firm or person, other than QLT and its directors and officers, any of the private affairs of QLT or any Confidential Information; or

Use – Use any Confidential Information that she may acquire for her own purposes or for any purposes, other than those of QLT.

Intellectual Property Rights

Disclose Inventions – Dr. Janes agrees to promptly disclose to QLT any and all ideas, developments, designs, articles, inventions, improvements, discoveries, machines, appliances, processes, methods, products or the like (collectively, “Inventions”) that Dr. Janes may invent, conceive, create, design, develop, prepare, author, produce or reduce to practice, either solely or jointly with others, in the course of her employment with QLT.

Inventions are QLT Property – All Inventions and all other work of Dr. Janes in the course of her employment with QLT will at all times and for all purposes be the property of, and are hereby assigned by Dr. Janes to, QLT for QLT to use, alter, vary, adapt and exploit as it will see fit, and will be acquired or held by Dr. Janes in a fiduciary capacity solely for the benefit of QLT.

Additional Requirements – Dr. Janes agrees to:

Treat all information with respect to Inventions as Confidential Information.

Keep complete and accurate records of Inventions, which records will be the property of QLT and copies of which records will be maintained at the premises of QLT.

Execute all assignments and other documents required to assign and transfer to QLT (or such other persons as QLT may direct) all right, title and interest in and to the Inventions and all other work of Dr. Janes in the course of her employment with QLT, and all writings, drawings, diagrams, photographs, pictures, plans, manuals, software and other materials, goodwill and ideas relating thereto, including, but not limited to, all rights to acquire in the name of QLT or its nominee(s) patents, registration of copyrights, design patents and registrations, trade marks and other forms of protection that may be available.

Execute all documents and do all acts reasonably requested by QLT to give effect to this provision.

Records – Dr. Janes agrees that all records or copies of records concerning QLT’s activities, business interests or investigations made or received by her during her employment with QLT are and will remain

the property of QLT. She further agrees to keep such records or copies in the custody of QLT and subject to its control, and to surrender the same at the termination of her employment or at any time during her employment at QLT’s request.

No Use of Former Employer’s Materials and Information – Dr. Janes certifies that she has not brought to QLT and will not use while performing her employment duties for QLT any materials or documents of any former employer which are not generally available to the public, except if the right to use the materials or documents has been duly licensed to QLT by the former employer. Dr. Janes certifies, warrants and represents that her performance of all provisions of this Agreement will not breach any agreement or other obligation to keep in confidence proprietary or confidential information known to her before or after the commencement of employment with QLT. Dr. Janes will not disclose to QLT, use in the performance of her work for QLT, or induce QLT to use, any Inventions (as defined above), confidential or proprietary information, or other material or documents belonging to any previous employer or to any other party in violation of any obligation of confidentiality to such party or in violation of such party’s proprietary rights; including without limitation whether any products or services of such previous employer or other person actually incorporated, used, or were designed or modified based upon such information, and even if such information constitutes negative know-how.

POST-EMPLOYMENT RESTRICTIONS

Non-Compete – Dr. Janes agrees that, by virtue of her senior position with QLT, she possesses and will possess strategic sensitive information concerning the business of QLT, its affiliates and subsidiaries. As a result, and in consideration of the payments to be made by QLT to Dr. Janes under this Agreement, without the prior written consent of QLT, for a period of one year following termination of her employment with QLT for any reason (by resignation or otherwise), as measured from her Last Active Day, Dr. Janes will not:

Participate in a Competitive Business – Directly or indirectly, own, manage, operate, join, control or participate in the ownership, management, operation or control of, or be a director or an employee of, or a consultant to, any business, firm or corporation that, as a part of conducting its business, is in any way competitive with QLT or any of its affiliates or subsidiaries with respect to:

the development and/or commercialization and/or marketing of pharmaceutical products that are directly competitive with QLT’s or its subsidiaries’ then current commercial products, Visudyne or any other products then being commercialized by or on behalf of QLT or its affiliates or subsidiaries which individually have worldwide annual net sales of U.S.$50 million or more in the calendar year preceding Dr. Janes’ Last Active Day,

the development and/or commercialization and/or marketing of light-activated pharmaceutical products for photodynamic therapy in the treatment of ophthalmic indications,

the development and/or commercialization and/or marketing of pharmaceutical products for treating ophthalmic indications associated with endogenous retinyl deficiencies in the eye, or

the development and/or commercialization and/or marketing of pharmacuetical products and/or devices that are or include lacrimal inserts and punctal plugs, and/or drug-eluting lacrimal implants and drug-eluting punctal plugs, and insertion, extraction and detection devices used in connection therewith, for the treatment or prevention for disease, including ocular diseases,

Solicit on Behalf of a Competitive Business – Directly or indirectly call upon or solicit any QLT employee or QLT customer or known prospective customer of QLT on behalf of any business, firm or corporation that, as part of conducting its business, is in any way competitive with QLT with respect to:

the development and/or commercialization and/or marketing of pharmaceutical products that are directly competitive with QLT’s or its subsidiaries’ then current commercial products, Visudyne or any other products then being commercialized by or on behalf of QLT or its affiliates or subsidiaries which individually have worldwide annual net sales of U.S.$50 million or more in the calendar year preceding Dr. Janes’ Last Active Day,

the development and/or commercialization and/or marketing of light-activated pharmaceutical products for photodynamic therapy in the treatment of ophthalmic indications,

the development and/or commercialization and/or marketing of pharmaceutical products for treating ophthalmic indications associated with endogenous retinyl deficiencies in the eye, or

the development and/or commercialization and/or marketing of pharmacuetical products and/or devices that are or include lacrimal inserts and punctal plugs, and/or drug-eluting lacrimal implants and drug-eluting punctal plugs, and insertion, extraction and detection devices used in connection therewith, for the treatment or prevention for disease, including ocular diseases,

Solicit Employees – Directly or indirectly solicit any individual to leave the employment of QLT or any of its affiliates or subsidiaries for any reason or interfere in any other manner with the employment relationship existing between QLT, its affiliates or subsidiaries and its current or prospective employees.

Solicit Customers – Directly or indirectly induce or attempt to induce any customer, supplier, distributor, licensee or other business relation of QLT or its affiliates or subsidiaries to cease doing business with QLT, its affiliates or subsidiaries or in any way interfere with the existing business relationship between any such customer, supplier, distributor, licensee or other business relation and QLT or its affiliates or subsidiaries.

Minority Share Interests Allowed – The parties agree that nothing contained in paragraph 8.1 is intended to prohibit Dr. Janes from owning less than 5% of the issued and outstanding stock of any company whose stock or shares are traded publicly on a recognized exchange.

REMEDIES

Irreparable Damage – Dr. Janes acknowledges and agrees that:

Breach – Any breach of any provision of this Agreement could cause irreparable damage to QLT; and

Consequences of Breach – In the event of a breach of any provision of this Agreement by Dr. Janes, QLT will have, in addition to any and all other remedies at law or in equity, the right to an injunction, specific performance or other equitable relief to prevent any violation by her of any of the provisions of this Agreement including, without limitation, the provisions of Sections 7 and 8.

Injunction – In the event of any dispute under Sections 7 and/or 8, Dr. Janes agrees that QLT will be entitled, without showing actual damages, to seek a temporary or permanent injunction restraining her conduct, pending a determination of such dispute and that no bond or other security will be required from QLT in connection therewith.

Additional Remedies – Dr. Janes acknowledges and agrees that the remedies of QLT specified in this Agreement are in addition to, and not in substitution for, any other rights and remedies of QLT at law or in equity and that all such rights and remedies are cumulative and not alternative or exclusive of any other rights or remedies and that QLT may have recourse to any one or more of its available rights and remedies as it will see fit.

GENERAL MATTERS

Tax Withheld – The parties acknowledge and agree that all payments to be made by QLT to Dr. Janes under this Agreement will be subject to QLT’s withholding of applicable withholding taxes.

Independent Legal Advice – Dr. Janes acknowledges that she has obtained or had the opportunity to obtain independent legal advice with respect to this Agreement and all of its terms and conditions.

Binding Agreement – The parties agree that this Agreement will enure to the benefit of and be binding upon each of them and their respective heirs, executors, successors and assigns.

Governing Law – The parties agree that this Agreement will be governed by and interpreted in accordance with the laws of the Province of British Columbia and the laws of Canada applicable to this Agreement. All disputes arising under this Agreement will be referred to the Courts of the Province of British Columbia, which will have exclusive jurisdiction, unless there is mutual agreement to the contrary.

Notice – The parties agree that any notice or other communication required to be given under this Agreement will be in writing and will be delivered personally or by facsimile transmission to the addresses set forth on page 1 of this Agreement to the attention of the following persons:

If to QLT – Attention: President and Chief Executive Officer, Fax No. (604) 707-7001,

If to Dr. Janes – To the address for Dr. Janes specified on page 1 of this Agreement;

Survival of Terms

Dr. Janes’ Obligations – Dr. Janes acknowledges and agrees that her representations, warranties, covenants, agreements, obligations and liabilities under any and all of Sections 7, 8 and 10 of this Agreement will survive any termination of this Agreement.

Company’s Obligations – QLT acknowledges and agrees that its representations, warranties, covenants, agreements, obligations and liabilities under any and all of Sections 3, 4, 5 and 10 of this Agreement will survive any termination of this Agreement.

Without Prejudice – Any termination of this Agreement will be without prejudice to any rights and obligations of the parties arising or existing up to the effective date of such expiration or termination, or any remedies of the parties with respect thereto.

Waiver – The parties agree that any waiver of any breach or default under this Agreement will only be effective if in writing signed by the party against whom the waiver is sought to be enforced, and no waiver will be implied by indulgence, delay or other act, omission or conduct. Any waiver will only apply to the specific matter waived and only in the specific instance in which it is waived.

Entire Agreement – The parties agree that the provisions contained in this Agreement, any Stock Option Agreements and the Change of Control Agreement entered into between QLT and Dr. Janes constitute the entire agreement between QLT and Dr. Janes with respect to the subject matters hereof and thereof, and supersede all previous communications, understandings and agreements (whether verbal or written) between QLT and Dr. Janes regarding the subject matters hereof and thereof. QLT and Dr. Janes hereby agree that the employment agreement previously entered into between them dated July 29, 2005 is terminated and replaced by this Agreement. To the extent that there is any conflict between the provisions of this Agreement, the Change of Control Agreement and any Stock Option Agreements, between QLT and Dr. Janes, the following provisions will apply:

Change of Control – If the conflict is with respect to an event, entitlement or obligation in the case of a Change of Control of QLT (as defined in the Change of Control Agreement entered into between QLT and Dr. Janes), the provisions of that Change of Control Agreement will govern (unless Dr. Janes otherwise elects as contemplated in paragraph 5.8 of this Agreement).

Stock Options – If the conflict is with respect to an entitlement or obligation with respect to stock options of QLT, the provisions of the Stock Option Agreements will govern (unless the parties otherwise mutually agree).

Other – In the event of any other conflict, the provisions of this Agreement will govern (unless the parties otherwise mutually agree).

Severability of Provisions – If any provision of this Agreement as applied to either party or to any circumstance is adjudged by a court of competent jurisdiction to be void or unenforceable for any reason, the invalidity of that provision will in no way affect (to the maximum extent permissible by law):

The application of that provision under circumstances different from those adjudicated by the court;

The application of any other provision of this Agreement; or

The enforceability or invalidity of this Agreement as a whole.

Captions – The parties agree that the captions appearing in this Agreement have been inserted for reference and as a matter of convenience and in no way define, limit or enlarge the scope or meaning of this Agreement or any provision.

Amendments – Any amendment to this Agreement will only be effective if the amendment is in writing and is signed by QLT and Dr. Janes.

By:

/s/ Robert L. Butchofsky

/s/ Lana Janes

ROBERT L. BUTCHOFSKY

DR. LANA JANES

PRESIDENT AND CHIEF EXECUTIVE OFFICER

)

)

)

)

(seal)  

)

LANA JANES

Name

)

)

Address

)

)

)

)

Occupation

)